Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

This case report documents a rare instance of triangular temporal alopecia in an adult woman, emphasizing the importance of correct diagnosis to avoid unnecessary treatments, and reviews the literature on TTA.

This analysis examines how faculty-related Instagram accounts have adapted their posts during the recent application cycle, including showcasing credentials and incorporating new virtual engagement tools, but reports no new research findings.

In this study, CTCF was found to play essential roles in epidermal differentiation and skin barrier formation, simultaneously acting as a suppressor of epithelial inflammatory responses in mouse skin.

Systemic mastocytosis may cause a type of hair loss called cicatricial alopecia.

This case report describes two patients with ulcerative colitis and alopecia areata who did not respond to various treatments but achieved remission and improved hair growth after starting tofacitinib.

This case report describes a successful treatment of alopecia universalis in a 37-year-old female using oral tofacitinib, along with other therapies, resulting in significant hair regrowth without notable safety concerns.

CTA is often mistaken for AA but doesn't respond to steroids and may require hair transplantation.

This report describes a case where the JAK inhibitor tofacitinib led to hair regrowth in a patient with alopecia totalis but also worsened facial acne, highlighting a unique adverse effect.

This letter discusses a previous study on tofacitinib for alopecia areata, questioning its statistical analysis and suggesting that steroids may have influenced results, but it reports no new clinical findings.

This study evaluated the efficacy and safety of tofacitinib for treating severe alopecia areata in five patients, finding that three responded favorably with mild side effects, supporting its potential use based on existing research.

This study found that Notch signalling promotes differentiation of epidermal cells and acts as a tumour suppressor in the skin by interacting with various pathways and mechanisms.

This case report describes a patient with painful skin lesions during sorafenib treatment whose symptoms improved after receiving photodynamic therapy, suggesting it might help manage similar refractory skin toxicity cases.

This study reported that a newly developed bioadhesive and injectable hydrogel dressing, incorporating hyaluronate-gelatin and the antibiotic doxycycline, accelerated burn wound healing and skin regeneration in rats, highlighting its potential for clinical applications in burn injury therapy.

This article provides an overview of the indications, interactions, and various potential adverse reactions associated with several drugs, but it reports no specific new results.

Ritlecitinib reduces alopecia areata symptoms by blocking JAK3/TEC signaling and T-cell activity.

This article discusses alopecia areata, highlighting its autoimmune nature and the lack of FDA-approved treatments, without providing new research findings.

This review highlights the potential of PROTAC technology in drug discovery for previously undruggable targets, particularly in cancer therapy, while emphasizing the urgent need to discover more E3 ligase recruiters to optimize targeted protein degradation.

This study found that tadalafil use was associated with a decreased risk of major adverse cardiac events and venous thromboembolism in men with lower urinary tract symptoms.

This study reviewed various studies and concluded that Janus kinase inhibitors, particularly tofacitinib, seem to promote hair regrowth in about half of patients with alopecia areata, though expected class-specific adverse effects were observed.

This study found that treatment with the polyphenolic compound TCQA activated β-catenin, promoting hair regrowth and the initiation of the anagen phase in mice and human dermal papilla cells.

Most patients with Tuberous sclerosis had neurological or skin issues, and over half had psychiatric problems.

Many patients with alopecia areata relapse after stopping tofacitinib.

The chemical peel improved the appearance of hand spots safely and effectively.

This study found that tianeptine may suppress the transition to catagen, promoting hair growth in a stress-induced alopecia areata mouse model.

In this randomized controlled trial, researchers are assessing the efficacy and safety of acupoint catgut embedding combined with topical 5% minoxidil in treating androgenetic alopecia among 70 men, with primary outcomes focusing on changes in hair count after 24 weeks of treatment.

This study suggests that 3,4,5-tri-O-caffeoylquinic acid activates β-catenin to enhance pigmentation in mouse hair follicles, human melanocytes, and melanoma cells during the hair cycle's growth phase.

In this study, tofacitinib treatment significantly reduced hair loss on the head and body, as well as nail involvement, in patients with alopecia areata over 18 months, with minimal side effects reported.

In this study, the researchers found that treatment with the JAK inhibitor tofacitinib in alopecia areata patients may reduce clonal CD8+ T cell expansions but does not eliminate them entirely, which could contribute to disease relapse.

This case report describes a 43-year-old male with alopecia totalis who successfully regrew all his hair after six months of treatment with tofacitinib, with no relapse at one year.

This study found that in a mouse model of alopecia areata, tofacitinib inhibited CD8+ T cell infiltration at hair follicles by modulating linoleic acid metabolism and magnesium pathways, offering insights into potential therapeutic strategies for the condition.